Biosimilars Immunology Roundup for May 2023—Podcast Edition
Season 6, Episode 11, Jun 04, 2023, 11:00 AM
On this episode, we’re going to be recapping some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.
Show Notes
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology